<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02542332</url>
  </required_header>
  <id_info>
    <org_study_id>Lung Cancer screening</org_study_id>
    <nct_id>NCT02542332</nct_id>
  </id_info>
  <brief_title>Are Doctors Familiar With the Test Characteristics of Lung Cancer Screening?</brief_title>
  <official_title>Are Doctors Familiar With the Test Characteristics of Lung Cancer Screening?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otto Wagner Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otto Wagner Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether doctors are familiar with the statistical background of lung
      cancer screening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Screening with low-dose CT scan can prevent three deaths due to lung cancer among
      1000 high-risk individuals. However, false-positive results and radiation exposure are
      relevant disadvantages deserving accurate consideration. Candidates for screening can only
      make an autonomous decision if doctors inform them correctly about the pros and cons of the
      method. Therefore, this study aims to evaluate, whether doctors understand the test
      characteristics of lung cancer screening.

      Methods: In a randomized trial, 556 doctors (members of the Austrian Respiratory Society)
      will be invited to answer questions regarding lung cancer screening based on online case
      vignettes. Half of the participants will be randomized to the group 'with data' and will
      receive the correct solutions in advance. The group 'without data' will have to rely on prior
      knowledge or estimate. Primary endpoint will be the between-groups difference in the
      estimated number of deaths preventable by screening. Secondary endpoints will be the
      between-groups differences in prevalence of lung cancer, prevalence of suspicious results,
      sensitivity, specificity, positive-predictive value, and false negative rate. Estimations
      will also be compared to actual values from the literature.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Between-groups difference in the estimated reduction of mortality due to lung cancer screening</measure>
    <time_frame>14 days</time_frame>
    <description>Participants had 14 days to complete the survey</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Between-groups difference prevalence of lung cancer</measure>
    <time_frame>14 days</time_frame>
    <description>Participants had 14 days to complete the survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-groups difference in sensitivity of lung cancer screening</measure>
    <time_frame>14 days</time_frame>
    <description>Participants had 14 days to complete the survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-groups difference in the frequency of a positive test result</measure>
    <time_frame>14 days</time_frame>
    <description>Participants had 14 days to complete the survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-groups difference in specificity of lung cancer screening</measure>
    <time_frame>14 days</time_frame>
    <description>Participants had 14 days to complete the survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-groups difference in positive predictive value of lung cancer screening</measure>
    <time_frame>14 days</time_frame>
    <description>Participants had 14 days to complete the survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-groups difference in the false negative rate of lung cancer screening</measure>
    <time_frame>14 days</time_frame>
    <description>Participants had 14 days to complete the survey</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">556</enrollment>
  <condition>Information About the Knowledge on the Statistical Background of Lung Cancer Screening of Doctors</condition>
  <arm_group>
    <arm_group_label>With Data</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received statistical data about lung cancer screening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without Data</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants had no statistical data on lung cancer screening</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>With Data</intervention_name>
    <description>The participants received statistical data about lung cancer screening in order to help them answer the questionaire</description>
    <arm_group_label>With Data</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Doctors, who were in training or had a completed specialization training in:

          -  Pneumonology

          -  Internal Medicine

          -  Surgery

          -  or Radiology

        Exclusion Criteria:

          -  Doctors, with a specialized training in

          -  ENT

          -  Pediatrics

          -  Pathology and doctors who had no e-mail address were excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georg-Christian Funk, Assoc.Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Otto Wagner Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Couraud S, Cortot AB, Greillier L, Gounant V, Mennecier B, Girard N, Besse B, Brouchet L, Castelnau O, Frappé P, Ferretti GR, Guittet L, Khalil A, Lefebure P, Laurent F, Liebart S, Molinier O, Quoix E, Revel MP, Stach B, Souquet PJ, Thomas P, Trédaniel J, Lemarié E, Zalcman G, Barlési F, Milleron B; French lung cancer screening statement taskforce; groupe d'Oncologie de langue française. From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d'Oncologie de langue francaise (GOLF). Ann Oncol. 2013 Mar;24(3):586-97. doi: 10.1093/annonc/mds476. Epub 2012 Nov 7.</citation>
    <PMID>23136229</PMID>
  </reference>
  <reference>
    <citation>Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990 Apr;11(2):116-28.</citation>
    <PMID>2161310</PMID>
  </reference>
  <reference>
    <citation>Gigerenzer G, Mata J, Frank R. Public knowledge of benefits of breast and prostate cancer screening in Europe. J Natl Cancer Inst. 2009 Sep 2;101(17):1216-20. doi: 10.1093/jnci/djp237. Epub 2009 Aug 11.</citation>
    <PMID>19671770</PMID>
  </reference>
  <reference>
    <citation>Herth FJ, Hoffmann H, Heussel CP, Biederer J, Gröschel A. [Lung cancer screening--update 2014]. Pneumologie. 2014 Dec;68(12):781-3. doi: 10.1055/s-0034-1390899. Epub 2014 Dec 9. German.</citation>
    <PMID>25489865</PMID>
  </reference>
  <reference>
    <citation>Hoffrage U, Gigerenzer G. Using natural frequencies to improve diagnostic inferences. Acad Med. 1998 May;73(5):538-40.</citation>
    <PMID>9609869</PMID>
  </reference>
  <reference>
    <citation>Horeweg N, Scholten ET, de Jong PA, van der Aalst CM, Weenink C, Lammers JW, Nackaerts K, Vliegenthart R, ten Haaf K, Yousaf-Khan UA, Heuvelmans MA, Thunnissen E, Oudkerk M, Mali W, de Koning HJ. Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers. Lancet Oncol. 2014 Nov;15(12):1342-50. doi: 10.1016/S1470-2045(14)70387-0. Epub 2014 Oct 1.</citation>
    <PMID>25282284</PMID>
  </reference>
  <reference>
    <citation>Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Sugarbaker DJ, Swanson SJ, Travis WD, Jaklitsch MT. Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. J Thorac Cardiovasc Surg. 2012 Jul;144(1):25-32. doi: 10.1016/j.jtcvs.2012.05.059.</citation>
    <PMID>22710038</PMID>
  </reference>
  <reference>
    <citation>Jaklitsch MT, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Swanson SJ, Travis WD, Sugarbaker DJ. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg. 2012 Jul;144(1):33-8. doi: 10.1016/j.jtcvs.2012.05.060.</citation>
    <PMID>22710039</PMID>
  </reference>
  <reference>
    <citation>Nuovo J, Melnikow J, Chang D. Reporting number needed to treat and absolute risk reduction in randomized controlled trials. JAMA. 2002 Jun 5;287(21):2813-4.</citation>
    <PMID>12038920</PMID>
  </reference>
  <reference>
    <citation>Rasmussen JF, Siersma V, Pedersen JH, Brodersen J. Psychosocial consequences in the Danish randomised controlled lung cancer screening trial (DLCST). Lung Cancer. 2015 Jan;87(1):65-72. doi: 10.1016/j.lungcan.2014.11.003. Epub 2014 Nov 20.</citation>
    <PMID>25433982</PMID>
  </reference>
  <reference>
    <citation>Schulz C. [Lung cancer screening and management of small pulmonary nodules]. Dtsch Med Wochenschr. 2015 Mar;140(5):317-22. doi: 10.1055/s-0041-100760. Epub 2015 Mar 3. German.</citation>
    <PMID>25734672</PMID>
  </reference>
  <reference>
    <citation>Simmons J, Gould MK, Woloshin S, Schwartz LM, Wiener RS. Attitudes about low-dose computed tomography screening for lung cancer: a survey of American Thoracic Society Clinicians. Am J Respir Crit Care Med. 2015 Feb 15;191(4):483-6. doi: 10.1164/rccm.201409-1747LE.</citation>
    <PMID>25679109</PMID>
  </reference>
  <reference>
    <citation>Wegwarth O, Gigerenzer G. &quot;There is nothing to worry about&quot;: gynecologists' counseling on mammography. Patient Educ Couns. 2011 Aug;84(2):251-6. doi: 10.1016/j.pec.2010.07.025. Epub 2010 Aug 16.</citation>
    <PMID>20719463</PMID>
  </reference>
  <reference>
    <citation>Wegwarth O, Schwartz LM, Woloshin S, Gaissmaier W, Gigerenzer G. Do physicians understand cancer screening statistics? A national survey of primary care physicians in the United States. Ann Intern Med. 2012 Mar 6;156(5):340-9. doi: 10.7326/0003-4819-156-5-201203060-00005.</citation>
    <PMID>22393129</PMID>
  </reference>
  <results_reference>
    <citation>National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395-409. doi: 10.1056/NEJMoa1102873. Epub 2011 Jun 29.</citation>
    <PMID>21714641</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <last_update_submitted>September 4, 2015</last_update_submitted>
  <last_update_submitted_qc>September 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Otto Wagner Hospital</investigator_affiliation>
    <investigator_full_name>Georg-Christian Funk</investigator_full_name>
    <investigator_title>Priv. Doz. Dr.</investigator_title>
  </responsible_party>
  <keyword>lung cancer screening</keyword>
  <keyword>statistical background</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

